Abstract 1019P
Background
The efficacy of immune checkpoint inhibitors (ICIs) in SMARCA4 mutant non-small cell lung cancer (NSCLC) is limited. CD8+ T cell exhaustion plays an important role in damaging anti-tumor immunity, but the molecular mechanisms remain unclear.
Methods
We compared the survival difference between patients with SMARCA4 mutation and wild type. The RNA sequencing of CD8+T cells sorted from tumor tissues was performed. The SMARCA4 mutant-H1299 cells were implanted into the left flank of the NSG mice. 2×107 human PBMCs were separated and injected intravenously into NSG mice to establish humanized NSG mouse models. Anti-PD-1 of Bispecific PD1-IL2 antibody were given intraperitoneally. The frequencies and phenotypes of CD8+T cells in mouse spleens and blood were detected by flow cytometry while those in tumor tissues were determined by multiplex immunofluorescence (mIF). The mIF staining was performed to validate differences of CD8+ T cells exhaustion phenotype between SMARCA4 mutant and wild-type patient tissues.
Results
Treatment with ICIs could not improve outcomes in patients with SMARCA4 mutations (P = 0.754). The analysis of RNA sequencing showed that the production of interleukin-2 (IL-2) was significantly reduced in CD8+T cells of SMARCA4 mutant Lewis lung carcinoma (P < 0.001). The analysis of mIF revealed that the infiltration of PD1+CD8+, LAG3+CD8+, TIM3+CD8+ T cells increased in SMARCA4 mutant tumor tissues. We found that a high level of IL-2 leads to the persistent activation of STAT5 in CD8+ T cells. Bispecific PD1-IL2 antibody enhanced anti-tumor immunity and suppressed tumor progression by reversing CD8+T cells exhaustion.
Conclusions
The PD1-IL2 bispecific antibody could reverse CD8+T cell exhaustion to enhance anti-tumor immunity in SMARCA4 mutant NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
H. Wang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
927P - Preliminary results of the BROADEN study: Burden of human papillomavirus-related head and neck cancers
Presenter: Laia Alemany
Session: Poster session 03
928P - Radiomic analysis based on machine learning of multi-MR sequences to assess early treatment response in locally advanced nasopharyngeal carcinoma
Presenter: Lei Qiu
Session: Poster session 03
929P - Advanced laryngeal squamous cell carcinoma prognosis and machine learning insights
Presenter: Tala Alshwayyat
Session: Poster session 03
Resources:
Abstract
930P - Real-world data analysis of oncological outcomes in patients with pathological extranodal extension (ENE) in OSCC: A proposal to refine the pathological nodal staging system
Presenter: Abhinav Thaduri
Session: Poster session 03
931P - Deep learning models for predicting short-term efficacy in locally advanced nasopharyngeal carcinoma
Presenter: Kexin Shi
Session: Poster session 03
932P - Accuracy and prognostic implications of extranodal extension on radiologic imaging in HPV-positive oropharyngeal cancer (HNCIG-ENE): A multinational, real-world study
Presenter: Hisham Mehanna
Session: Poster session 03
933P - Prediction of survival in patients with head and neck merkel cell carcinoma: Statistical and machine-learning approaches
Presenter: Jehad Yasin
Session: Poster session 03
934P - Harnessing artificial intelligence on real-world data to predict recurrence in head and neck squamous cell carcinoma patients: The HNC-TACTIC study
Presenter: Hisham Mehanna
Session: Poster session 03
936P - Chronic pain in cancer survivors: Head and neck versus other cancers
Presenter: Rong Jiang
Session: Poster session 03